SHANGHAI and BOSTON, Jan. 11, 2026 /PRNewswire/ — Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, today announced that Dr. Dongxu Shu, Co-Founder, Chairman of the Board, and Chief Executive Officer will present at the 44^th Annual J.P. Morgan Healthcare Conference on Thursday, January 15^th 2026 at 1:15 PM PST / 4:15 PM EST. in San Francisco, CA.

About Argo Biopharma

Argo Biopharma is a clinical-stage biotechnology company committed to developing next-generation RNAi therapeutics to provide better treatment options for patients worldwide. The company has established a robust and diverse pipeline of RNAi molecule candidates targeting a wide range of indications, including cardiovascular diseases, viral infections, metabolic conditions, and specialty/rare diseases. Currently, Argo Biopharma has six RNAi candidates in clinical development.

For more information, visit www.argobiopharma.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/argo-biopharma-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302658037.html

SOURCE Argo Biopharmaceutical Co., Ltd